Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate‐to‐severe atopic dermatitis: A network meta‐analysis-Reference-Cited by-同舟云学术

Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate‐to‐severe atopic dermatitis: A network meta‐analysis

Published:2022-07-27 Issue:9 Volume:35 Page:
ISSN:1396-0296
Container-title:Dermatologic Therapy
language:en
Short-container-title:Dermatologic Therapy

Author:

Wan Huiying¹,Jia Haiping²,Xia Tian³^ORCID,Zhang Dingding⁴

Affiliation:

1. Department of Dermatology, Sichuan Provincial People's Hospital University of Electronic Science and Technology of China Chengdu China

2. Department of Immunology and Microbiology, North Sichuan Medical College Nanchong China

3. Department of Pathology, The 452nd Hospital of People's Liberation Army Chengdu China

4. Sichuan Provincial Key Laboratory for Genetic Disease, Sichuan Provincial People's Hospital University of Electronic Science and Technology of China Chengdu China

Funder

Department of Science and Technology of Sichuan Province

Publisher

Hindawi Limited

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dth.15636

Reference57 articles.

1. Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape

2. Atopic dermatitis

3. Epidemiology of atopic dermatitis: a review

4. Adult eczema prevalence and associations with asthma and other health and demographic factors: A US population–based study

5. Psoriasis

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Off-Label Uses of Abrocitinib: Review of Emerging Therapeutic Applications beyond Atopic Dermatitis;Life;2024-09-06

2. DERMATITE ATÓPICA E CONJUNTIVITE ALÉRGICA: FATORES PRECIPITANTES E ESTRATÉGIAS DE MANEJO;Revista Contemporânea;2024-08-02

3. Evolution of dupilumab‐associated conjunctivitis in patients with atopic dermatitis after switching dupilumab to tralokinumab or Janus kinase inhibitors (RESO‐ADOC study);Journal of the European Academy of Dermatology and Venereology;2024-07-17

4. Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A Narrative Review;Dermatology and Therapy;2024-07-16

5. Efficacy and Safety of Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Meta-Analysis;Cureus;2024-07-13